HLX07 placebo
Sponsors
Shanghai Henlius Biotech
Conditions
Head and Neck Squamous Cell CarcinomaSquamous NSCLC
Phase 2
Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors
NCT04297995
Start: 2020-07-29End: 2025-06-30Target: 131Updated: 2023-08-08
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
Not yet recruitingNCT07318883
Start: 2026-03-31End: 2031-01-31Target: 720Updated: 2026-01-06